Kanen Wealth Management LLC Cuts Holdings in The Oncology Institute, Inc. $TOI

Posted by on Jul 29th, 2026

Kanen Wealth Management LLC lessened its holdings in shares of The Oncology Institute, Inc. (NASDAQ:TOI – Free Report) by 6.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,777,858 shares of the company’s stock after selling 198,286 shares during the quarter. Oncology Institute makes up 3.1% of Kanen Wealth Management LLC’s portfolio, making the stock its 9th biggest position. Kanen Wealth Management LLC owned 2.81% of Oncology Institute worth $8,528,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Kestra Advisory Services LLC bought a new stake in Oncology Institute in the fourth quarter worth $31,000. Pekin Hardy Strauss Inc. bought a new position in shares of Oncology Institute during the fourth quarter valued at $36,000. Cetera Investment Advisers increased its holdings in shares of Oncology Institute by 35.0% during the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after acquiring an additional 4,545 shares in the last quarter. State of Wyoming purchased a new position in shares of Oncology Institute in the 2nd quarter worth about $37,000. Finally, R Squared Ltd purchased a new position in shares of Oncology Institute in the 4th quarter worth about $41,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Oncology Institute Price Performance

Oncology Institute stock opened at $4.95 on Wednesday. The Oncology Institute, Inc. has a one year low of $2.32 and a one year high of $6.67. The stock has a market capitalization of $489.26 million, a PE ratio of -13.38 and a beta of 0.36. The business’s fifty day moving average is $5.15 and its 200 day moving average is $3.89.

Oncology Institute (NASDAQ:TOI – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The business had revenue of $147.44 million during the quarter, compared to analysts’ expectations of $142.10 million. As a group, sell-side analysts expect that The Oncology Institute, Inc. will post -0.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Jorey Chernett acquired 18,000 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The stock was purchased at an average cost of $5.27 per share, with a total value of $94,860.00. Following the completion of the acquisition, the insider directly owned 10,648,858 shares of the company’s stock, valued at approximately $56,119,481.66. This trade represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Yale Podnos sold 23,451 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the transaction, the insider owned 259,527 shares in the company, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders bought 131,500 shares of company stock valued at $609,265 over the last quarter. Company insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Friday, July 17th. Lake Street Capital started coverage on shares of Oncology Institute in a report on Monday, July 6th. They issued a “buy” rating and a $10.00 target price for the company. Needham & Company LLC upped their target price on shares of Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Finally, BTIG Research increased their price target on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

View Our Latest Stock Report on TOI

About Oncology Institute

(Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.

Featured Articles

Want to see what other hedge funds are holding TOI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Oncology Institute, Inc. (NASDAQ:TOI – Free Report).

Institutional Ownership by Quarter for Oncology Institute (NASDAQ:TOI)

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.